Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 25, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It reports a single transaction involving GlaxoSmithKline plc American Depositary Shares (ADSs).
- Instrument: GlaxoSmithKline plc ADSs (ISIN: US37733W1053)
- Transaction Price: $43.88 per ADS
- Transaction Volume: 1 ADS
- Transaction Date: July 22, 2016
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an increase of 1 ADS for Dr. K. Slaoui (PCA of Dr. M. M. Slaoui, Chairman, Global Vaccines) resulting from the revaluation of the cash element of a notional investment within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a specific securities transaction.
Investor Verification Points
- Verify the identity of the PCA (Dr. K. Slaoui) and their relationship to the PDMR (Dr. M. M. Slaoui).
- Confirm the transaction was an automatic allocation via the GSK 401(K) plan revaluation rather than an open market purchase.
- Note that this filing does not reflect broader company performance; refer to Form 20-F for financial results.